Fungicide Sparks Neurotoxicity Fears: Study Rewrites Safety Data

A recent study has cast serious doubt on the safety of the fungicide fluazinam, suggesting it may negatively impact brain development. Researchers at Stockholm University, using the same statistical methods as a 2005 study by Huntingdon Life Sciences, found six instances where exposure to fluazinam led to statistically significant adverse effects in rat offspring, including decreased brain weight and width. These new findings directly contradict the 2005 report, which concluded no significant effects. The authors of the new study state that the original conclusions were unreasonable and unsupported by the raw data. This raises concerns about the 2008 EU approval of fluazinam, as failing to report such significance could breach regulations. Fluazinam, used on potatoes and apples, saw 340 tonnes sold in Germany alone in 2024. Campaign group Pesticide Action Network (PAN) Europe is calling for an urgent investigation and immediate market withdrawal, citing a breach of legal obligations and scientific integrity. The fungicide is currently under re-evaluation for EU approval, with its authorization in the UK valid until 2029. Experts reviewing the new study agree that fluazinam should not have been approved for use based on these findings. Continued use since 2008 may have led to harmful human exposure, with the fungicide detected near children's playgrounds in Italy. While animal studies cannot be directly extrapolated to humans, the researchers emphasize that harm to rat brain development suggests potential risks for humans. Concerns have also been raised about the EU's pesticide approval system, where companies producing pesticides are responsible for providing safety data, creating a potential conflict of interest. The European Food Safety Authority (EFSA) has requested a review of fluazinam's statistical analysis and data by the Austrian Agency for Health and Food Safety (AGES), with conclusions expected by the first quarter of 2027. Manufacturers ISK stated they are awaiting the underlying analysis and trust regulatory processes.